The PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity, while PIM-1 and PIM-3 are positive regulators, report Medical University of South Carolina (MUSC) investigators in an article ...
Jun 15, 2018
0
30
The U.S. Food and Drug Administration has approved Litfulo (ritlecitinib) for adults and adolescents aged 12 years and older with severe alopecia areata at a recommended dose of 50 mg. Approval of Litfulo was granted to Pfizer.
Jun 27, 2023
0
1
A new study by scientists at the University of Liverpool highlights how a clinically-approved lung cancer drug could potentially be 'repurposed' to design new treatments for future cancer therapies.
Sep 25, 2018
0
121
Patients with Alzheimer's disease (AD) have lower levels of the neuromodulator acetylcholine (ACh) in their brains. Donepezil, an AD drug, increases brain ACh levels and improves AD-associated learning deficits. Now, researchers ...
Jun 27, 2022
0
6
(Medical Xpress)—If life were simple, a disease could be treated with one drug that hits one molecular target, like striking a piano key. Instead, researchers wrestle with the fact that most drugs hit multiple targets in ...
Mar 20, 2014
0
0
Johns Hopkins and National Taiwan University researchers have discovered more details about how an energy sensing "thermostat" protein determines whether cells will store or use their energy reserves.
Feb 21, 2012
0
0
Most patients with chronic myelogenous leukemia can be treated with tyrosine kinase inhibitors. These drugs are highly effective and lead to deep remission and prolonged survival. Yet quiescent leukemic stem cells persist ...
Mar 21, 2019
0
6
A class of cancer drugs called protein kinase inhibitors is one of the most effective treatments for melanoma. However, in many cases, tumors eventually become resistant to the drugs and cause a relapse in the patient.
Dec 3, 2018
0
221
Precision medicine in cancer treatment uses genetic changes in the cancer cells to select the best therapies for individual patients.
Jul 28, 2020
0
127
In 2011, Igor Stagljar, a professor in the University of Toronto's Donnelly Centre, came across a study that genetically linked two genes in the cell to a hard-to-treat (triple negative) breast cancer. It was not clear how ...
Jan 5, 2017
0
150
